Philips launches its first clinical product for aiding cognitive assessment in the U.S.
November 12 2019 - 9:00AM
November 12, 2019
Philips IntelliSpace Cognition provides U.S. healthcare
professionals with a powerful aid for assessing cognitive
impairments due to neurological conditions
Amsterdam, the Netherlands and Cambridge, U.S.
– Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in
health technology, announced today the U.S. debut of its new
cognitive assessment platform IntelliSpace Cognition. Leveraging
the power of artificial intelligence (AI) and Philips’ cloud-based
HealthSuite Digital Platform, IntelliSpace Cognition provides
healthcare professionals with a powerful aid for assessing
cognitive impairment.
IntelliSpace Cognition automates and enhances well-established
neuropsychological tests, offering new insights for clinicians
treating patients with debilitating neurological conditions. It
provides direct access to detailed information about a patient’s
cognition while also providing quantitative longitudinal data to
aid in assessing disease progression and treatment efficacy."There
is a real need for quantitative measures to assess the cognitive
impairment of people with neurological disease,” said Dr. Joseph
Fritz, CEO of DENT Neurologic Institute, the first neurology
practice to use IntelliSpace Cognition. “Computerized tools and
intelligent algorithms offer new opportunities in this area to
improve care. The depth of information now available and the
efficiency with which we can perform assessments can be very
helpful for providing feedback to patients and families sooner and
developing treatment plans more quickly.”
“While dealing with the rising tide of neurological disease
remains a great challenge, our solution will facilitate robust and
reliable cognitive assessment with greater efficiency and scale
than traditional methods,” said Jeroen Tas, Chief Innovation &
Strategy Officer at Philips. “Combining this with imaging-based
diagnostics we aim to offer care providers more meaningful insights
into the health of their patients and potentially open up new
possibilities for treatment in the future.”
A crucial care pathway for neurologists is to refer patients to
neuropsychologists whose expertise in assessing cognitive issues
provides important information for treatment. While treatment may
be limited for some neurodegenerative diseases, it is vital to act
as early as possible to establish an appropriate care plan or
treatment protocol.
The number of neuropsychologists able to perform an assessment
is limited and coupled with a rise in the number of patients
suffering from neurological conditions, there is a need for new
innovative solutions. A rapid and reliable method for neurologists
to better assess cognition and select those that would benefit from
seeing a neuropsychologist would alleviate pressure on this part of
the healthcare system. Results from a study conducted by Philips
support interest in new solutions to address these issues.
Ninety-two percent of neurologists indicated that the IntelliSpace
Cognition concept would be appealing to use within their practice
[1].
Philips has invested in collecting insights from both
neurologists and neuropsychologists in order to design IntelliSpace
Cognition in an iterative manner and ensure it fits into the
majority of existing workflows. IntelliSpace Cognition was
developed under a quality management system for medical devices and
has undergone rigorous usability testing and a monitored clinical
trial has been performed to validate the digital cognitive tests
and collect normative data from healthy individuals that reflect
the U.S. population. The Philips study found that 80% of
neurologists said they would feel confident using IntelliSpace
Cognition because Philips has collected normative data to provide
peer comparisons to a healthy group.
In the typical workflow, illustrated in this video, a patient
performs various tests on a tablet under minimal supervision of an
assistant with audio prompts to guide in tasks such as drawing a
clock, joining numbered dots or remembering a sequence of numbers.
The results of the tests are then communicated to IntelliSpace
Cognition’s cloud-based computing platform, where advanced
validated algorithms perform analytics to present the clinician
with the results. IntelliSpace Cognition is just one part of an
expanding neurology IT portfolio of Philips which includes,
neuroimaging, high density EEG and now digital cognitive
assessment.
IntelliSpace Cognition will initially be commercially available
only in the U.S.
[1] Based on a 2019 Philips study of 100 neurologists in the
U.S.
For further information, please contact:
Joost MalthaPhilips Global Press OfficeTel: +31 6 10 55
8116E-mail: joost.maltha@philips.comTwitter: @JoostMaltha
Avi DinesPhilips North AmericaTel: +1 781-690-3814E-mail:
avi.dines@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
enabling better outcomes across the health continuum from healthy
living and prevention, to diagnosis, treatment and home care.
Philips leverages advanced technology and deep clinical and
consumer insights to deliver integrated solutions. Headquartered in
the Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2018
sales of EUR 18.1 billion and employs approximately 80,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
- Philips IntelliSpace Cognition 1
- Philips IntelliSpace Cognition 2
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Sep 2023 to Sep 2024